---
category: news
title: "Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter"
excerpt: "Kiromic achieves key milestone for this first-in-human Phase 1 clinical trial with a target derived by Kiromicâ€™s AI platform. HOUSTON-- ( BUSINESS WIRE )--Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics,"
publishedDateTime: 2021-05-24T15:55:00Z
originalUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
webUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
type: article

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI in Healthcare
  - AI

secured: "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;TKE6NdQS4o7loHaC0j0g7A=="
---

